Bayer AG Advances Parkinson’s Treatment with Promising Gene Therapy Study

Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.

Study Overview: Bayer AG, in collaboration with AskBio Inc, is conducting a Phase 2 clinical study titled A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson’s Disease. The study aims to evaluate the safety and efficacy of AAV2-GDNF gene therapy in treating moderate Parkinson’s Disease, highlighting its potential significance in advancing treatment options for this condition.

Intervention/Treatment: The study tests AAV2-GDNF gene therapy, an experimental drug delivered via bilateral image-guided infusion into the putamen, and a control surgery involving sham procedures. The gene therapy is designed to potentially improve neurological function in Parkinson’s patients.

Study Design: This interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, aiming to assess the therapeutic benefits of the gene therapy.

Study Timeline: The study began on June 11, 2024, with an estimated primary completion date yet to be announced. The latest update was submitted on August 12, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

Market Implications: The study’s progress could significantly impact Bayer AG’s stock performance by potentially enhancing its portfolio in the neurological treatment sector. Positive outcomes may boost investor confidence and position Bayer competitively against other pharmaceutical companies exploring Parkinson’s treatments.

The study is currently ongoing, with further details available on the ClinicalTrials portal.